Talphera, Inc. (NASDAQ:TLPH – Get Free Report) CEO Vincent Angotti acquired 105,364 shares of the stock in a transaction that occurred on Thursday, February 12th. The stock was purchased at an average price of $0.81 per share, for a total transaction of $85,344.84. Following the completion of the purchase, the chief executive officer directly owned 586,954 shares in the company, valued at $475,432.74. This trade represents a 21.88% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Talphera Price Performance
NASDAQ:TLPH traded down $0.03 on Friday, reaching $0.78. 51,448 shares of the company’s stock were exchanged, compared to its average volume of 163,382. The firm has a market cap of $36.20 million, a price-to-earnings ratio of -2.04 and a beta of 0.46. The stock has a fifty day simple moving average of $1.00 and a 200-day simple moving average of $0.99. Talphera, Inc. has a 52 week low of $0.38 and a 52 week high of $1.57.
Institutional Trading of Talphera
Large investors have recently modified their holdings of the business. AIGH Capital Management LLC increased its position in shares of Talphera by 4.6% in the fourth quarter. AIGH Capital Management LLC now owns 4,661,502 shares of the company’s stock worth $5,314,000 after purchasing an additional 206,957 shares during the last quarter. Rosalind Advisors Inc. lifted its position in Talphera by 118.9% during the third quarter. Rosalind Advisors Inc. now owns 4,385,757 shares of the company’s stock valued at $3,917,000 after purchasing an additional 2,381,818 shares during the last quarter. Nantahala Capital Management LLC grew its stake in Talphera by 75.3% in the 3rd quarter. Nantahala Capital Management LLC now owns 3,492,519 shares of the company’s stock worth $3,120,000 after buying an additional 1,500,000 shares in the last quarter. Empery Asset Management LP bought a new position in shares of Talphera in the 4th quarter worth $1,520,000. Finally, Cantor Fitzgerald L. P. purchased a new stake in shares of Talphera during the 4th quarter valued at $658,000. Institutional investors own 37.67% of the company’s stock.
Analyst Upgrades and Downgrades
Check Out Our Latest Stock Report on Talphera
About Talphera
Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.
Featured Stories
- Five stocks we like better than Talphera
- From Quiet Compounder to 2026 Breakout? BSEM
- This $15 Stock Could Go Down as the #1 Stock of 2026
- Gilder: Don’t Buy AI Stocks, Do This Instead
- America’s 1776 happening again
- Sell this, buy that
Receive News & Ratings for Talphera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talphera and related companies with MarketBeat.com's FREE daily email newsletter.
